ES2947826T3 - Célula endotelial corneal funcional humana y aplicación de la misma - Google Patents

Célula endotelial corneal funcional humana y aplicación de la misma Download PDF

Info

Publication number
ES2947826T3
ES2947826T3 ES17709487T ES17709487T ES2947826T3 ES 2947826 T3 ES2947826 T3 ES 2947826T3 ES 17709487 T ES17709487 T ES 17709487T ES 17709487 T ES17709487 T ES 17709487T ES 2947826 T3 ES2947826 T3 ES 2947826T3
Authority
ES
Spain
Prior art keywords
cell
negative
cells
corneal endothelial
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17709487T
Other languages
English (en)
Spanish (es)
Inventor
Shigeru Kinoshita
Junji Hamuro
Chie Sotozono
Morio Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto Prefectural PUC
Original Assignee
Kyoto Prefectural PUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58261691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2947826(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyoto Prefectural PUC filed Critical Kyoto Prefectural PUC
Application granted granted Critical
Publication of ES2947826T3 publication Critical patent/ES2947826T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES17709487T 2016-02-15 2017-02-14 Célula endotelial corneal funcional humana y aplicación de la misma Active ES2947826T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2016026426 2016-02-15
JP2016026423 2016-02-15
JP2016026424 2016-02-15
JP2016026425 2016-02-15
JP2016077450 2016-04-07
PCT/JP2017/005386 WO2017141926A1 (en) 2016-02-15 2017-02-14 Human functional corneal endothelial cell and application thereof

Publications (1)

Publication Number Publication Date
ES2947826T3 true ES2947826T3 (es) 2023-08-21

Family

ID=58261691

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17709487T Active ES2947826T3 (es) 2016-02-15 2017-02-14 Célula endotelial corneal funcional humana y aplicación de la misma

Country Status (6)

Country Link
US (3) US20190083543A1 (https=)
EP (2) EP3416658B1 (https=)
JP (6) JP7008337B2 (https=)
ES (1) ES2947826T3 (https=)
PL (1) PL3416658T3 (https=)
WO (1) WO2017141926A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858173C (en) 2011-12-06 2023-09-26 Advanced Cell Technology, Inc. Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
EP3416658B1 (en) 2016-02-15 2023-03-22 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof
CN107629999A (zh) * 2017-10-18 2018-01-26 清华大学深圳研究生院 一种增加间充质干细胞外泌体产生及分泌的方法
US12350294B2 (en) 2018-01-16 2025-07-08 Keio University Medium comprising serum replacement, IGF1, STAT3 activator and adrenal gland hormone without BFGF or rock inhibitor for producing corneal endothelial substitute cells from iPS cells and a method thereof
EP3893904A4 (en) * 2018-12-12 2022-08-17 The Johns Hopkins University GENERATION AND CRYOPRESERVATION OF CLINICAL-QUALITY CORNEAL EDDELLIAL CELLS FROM PLURIPOTENTIC STEM CELLS
KR102446567B1 (ko) * 2019-04-17 2022-09-26 연세대학교 산학협력단 각막 내피 세포의 기능 부전 진단용 바이오마커
JP2020200296A (ja) * 2019-06-13 2020-12-17 久貴 藤本 角膜内皮障害の予防及び／又は治療のための薬剤
US12230397B2 (en) * 2019-08-21 2025-02-18 Case Western Reserve University Assessment of endothelial cells and corneas at risk from ophthalmological images
WO2021172554A1 (ja) 2020-02-27 2021-09-02 京都府公立大学法人 ヒト機能性角膜内皮細胞およびその応用
WO2022025239A1 (ja) * 2020-07-31 2022-02-03 学校法人同志社 角膜内皮細胞注入療法の治療効果増強法
AU2021366805B2 (en) * 2020-10-22 2025-04-24 Kyoto Prefectural Public University Corporation A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells
CN112538458B (zh) * 2020-11-26 2025-10-31 北京孟眸生物科技有限公司 用于重编程细胞的方法
US20240350552A1 (en) 2021-07-07 2024-10-24 Cellusion Inc. Therapeutic composition containing corneal endothelium replacement cells
WO2023282338A1 (ja) 2021-07-07 2023-01-12 株式会社セルージョン 細胞播種剤及び細胞移植用基材
CN114507635B (zh) * 2022-01-24 2024-03-22 上海纽仁生物医药科技有限公司 一种动物神经系统内皮细胞单细胞的分离方法
WO2023190941A1 (ja) * 2022-03-31 2023-10-05 学校法人同志社 培養由来成分を含まない角膜内皮細胞製剤及びその製造法
WO2023230171A2 (en) * 2022-05-24 2023-11-30 University Of Pittsburgh - Of Thecommonwealth System Of Highereducation Compositions and methods of treating corneal scarring
EP4655392A2 (en) * 2023-01-27 2025-12-03 Universiteit Maastricht Methods for selecting cultured corneal endothelial cells
WO2024182683A1 (en) * 2023-03-01 2024-09-06 The Regents Of The University Of California Rapid, accurate, and reproducible screening of endothelial cell morphology in diseased and healthy corneas
KR20250024502A (ko) * 2023-08-11 2025-02-18 재단법인 아산사회복지재단 분화 유도된 각막 내피 세포를 포함하는 각막 질환 예방 또는 치료용 약학적 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
JP3421217B2 (ja) 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
AU9646198A (en) 1997-10-22 1999-05-10 Nippon Shinyaku Co. Ltd. Isoquinoline derivative and drug
WO1999061403A1 (en) 1998-05-25 1999-12-02 Santen Pharmaceutical Co., Ltd. Novel vinylbenzene derivatives
EP1020534B2 (en) 1998-11-09 2011-01-05 Eiken Kagaku Kabushiki Kaisha Process for synthesizing nucleic acid
AU2878200A (en) 1999-02-11 2000-08-29 Schepens Eye Research Institute, Inc., The Growth medium for human corneal endothelial cells
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
US6690307B2 (en) 2002-01-22 2004-02-10 Nokia Corporation Adaptive variable length coding of digital video
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1541559A4 (en) 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2005003101A2 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
WO2005034866A2 (en) 2003-10-06 2005-04-21 Glaxo Group Limited Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
ES2387780T3 (es) 2003-10-06 2012-10-01 Glaxosmithkline Llc Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas
JP2007507547A (ja) 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，７−二置換アザベンゾイミダゾールの調製
JP2007015928A (ja) 2003-10-15 2007-01-25 Ube Ind Ltd 新規オレフィン誘導体
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
AR049333A1 (es) 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
WO2006057270A1 (ja) 2004-11-26 2006-06-01 Asahi Kasei Pharma Corporation 含窒素３環化合物
CA2621181C (en) 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
WO2009028631A1 (ja) * 2007-08-29 2009-03-05 Senju Pharmaceutical Co., Ltd. 角膜内皮細胞接着促進剤
EP2249800B1 (en) * 2008-02-04 2024-04-17 Jeffrey L. Goldberg Iron magnetic cells for localizing delivery and eye tissue repair
US8606848B2 (en) 2009-09-10 2013-12-10 Opentv, Inc. Method and system for sharing digital media content
WO2011080984A1 (en) * 2009-12-29 2011-07-07 Senju Pharmaceutical Co., Ltd. Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
JP5835693B2 (ja) * 2010-02-05 2015-12-24 株式会社角膜再生研究所 角膜内皮細胞の培養方法、移植用角膜内皮細胞シートの製造方法および角膜内皮細胞培養キット
EP2547082B1 (en) 2010-03-08 2019-06-26 Nec Corporation Mobile communication terminal apparatus, method for controlling power consumption of mobile communication terminal apparatus, and recording medium
KR102124149B1 (ko) 2010-05-12 2020-06-18 인터디지탈 매디슨 페이튼트 홀딩스 통합된 유효성 맵 코딩을 위한 방법 및 장치
EP2765188B1 (en) * 2011-10-06 2017-12-06 Keio University Method for producing corneal endothelial cell
ES2897740T3 (es) * 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
US9616101B2 (en) * 2012-07-06 2017-04-11 Kyoto Prefectural Public University Corporation Differentiation marker and differentiation control of eye cell
US10017735B2 (en) 2012-07-18 2018-07-10 Singapore Health Services Pte Ltd Cell culture of corneal endothelial cells
US10174284B2 (en) * 2012-09-07 2019-01-08 Jcr Pharmaceuticals Co., Ltd. Medium, for culturing corneal endothelial cells, containing conditioned medium from mesenchymal stem cells
EP3029140A4 (en) 2013-07-30 2017-06-28 Kyoto Prefectural Public University Corporation Corneal endothelial cell marker
WO2015072580A1 (ja) * 2013-11-14 2015-05-21 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
JP2016077450A (ja) 2014-10-15 2016-05-16 タツタ電線株式会社 医療用チューブ
EP3416658B1 (en) 2016-02-15 2023-03-22 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof

Also Published As

Publication number Publication date
WO2017141926A1 (en) 2017-08-24
US20260034177A1 (en) 2026-02-05
JP2019510509A (ja) 2019-04-18
JP2020072753A (ja) 2020-05-14
EP4218773A1 (en) 2023-08-02
JP2026012325A (ja) 2026-01-23
EP3416658B1 (en) 2023-03-22
JP2026021433A (ja) 2026-02-10
US20190083543A1 (en) 2019-03-21
PL3416658T3 (pl) 2023-09-04
JP7453669B2 (ja) 2024-03-21
JP2020073602A (ja) 2020-05-14
JP7008337B2 (ja) 2022-02-10
US20210046124A1 (en) 2021-02-18
JP6954682B2 (ja) 2021-10-27
JP2024019306A (ja) 2024-02-08
EP3416658A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
ES2947826T3 (es) Célula endotelial corneal funcional humana y aplicación de la misma
Le Saux et al. A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis
CN106456694B (zh) 与循环肿瘤细胞相关的方法和测定法
EP2399129B1 (en) A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US20250123297A1 (en) Supermere Nanoparticles and Methods of Isolation and Use Thereof
Sun et al. Cisd2 plays an essential role in corneal epithelial regeneration
Park et al. Sonic hedgehog, a novel endogenous damage signal, activates multiple beneficial functions of human endometrial stem cells
TW201936195A (zh) 胺甲喋呤誘發的免疫耐受性之生物標記
US20170202910A1 (en) Differentiation marker and differentiation control of eye cell
Lyu et al. Protein kinase A inhibitor H89 attenuates experimental proliferative vitreoretinopathy
Tu et al. CD164 regulates proliferation and apoptosis by targeting PTEN in human glioma
Goldsmith et al. Targeting the platelet-derived growth factor-beta stimulatory circuitry to control retinoblastoma seeds
Loomans et al. Loss of ACVRIB leads to increased squamous cell carcinoma aggressiveness through alterations in cell-cell and cell-matrix adhesion proteins
Cao et al. Thymopentin ameliorates experimental colitis via inhibiting neutrophil extracellular traps
HK40097456A (en) Human functional corneal endothelial cell and application thereof
US10087435B2 (en) Methods and compounds for reducing threonyl-tRNA synthetase activity
Karna et al. A genetic signature predicts aggressive paraganglioma sensitivity to dual PI3K-CDK4/6 inhibition therapy
CN103820528B (zh) Reelin及其拮抗剂在骨髓瘤患者分期及预后中的新应用
Sagers Novel Mechanistic Insights and Therapeutic Strategies for Vestibular Schwannoma and Neurofibromatosis Type 2
US20250114470A1 (en) Therapy for polycystic kidney disease
Hayden et al. Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
Meena et al. Repurposing Nelfinavir: AIM2 Inflammasome-Driven Anti-tumor Effects in Glioblastoma
Martins P-cadherin as a phenotypic stability factor of the hybrid epithelial/mesenchymal phenotype in breast cancer
Mudry CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines
Santi The tumor microenvironment: insight into fibroblasts pathophysiological functions